[{"address1": "The Omeros Building", "address2": "201 Elliott Avenue West", "city": "Seattle", "state": "WA", "zip": "98119", "country": "United States", "phone": "206 676 5000", "website": "https://www.omeros.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.", "fullTimeEmployees": 198, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gregory A. Demopulos M.D.", "age": 64, "title": "Co-Founder, Chairman, CEO & President", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 5965279, "exercisedValue": 0, "unexercisedValue": 39325}, {"maxAge": 1, "name": "Mr. Peter B. Cancelmo J.D.", "age": 44, "title": "VP, General Counsel & Corporate Secretary", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 611435, "exercisedValue": 0, "unexercisedValue": 5500}, {"maxAge": 1, "name": "Dr. Pamela Pierce Palmer M.D., Ph.D.", "age": 60, "title": "Co-Founder", "yearBorn": 1963, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. David J. Borges", "age": 59, "title": "VP of Finance, Chief Accounting Officer & Treasurer", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. George A. Gaitanaris M.D., Ph.D.", "age": 66, "title": "Chief Scientific Officer & VP of Science", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Peter W. Williams", "age": 55, "title": "Vice President of Human Resources", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Catherine A. Melfi Ph.D.", "age": 64, "title": "Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nadia  Dac", "age": 53, "title": "VP & Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andreas  Grauer M.D.", "age": 62, "title": "VP & Chief Medical Officer", "yearBorn": 1961, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 5, "overallRisk": 10, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 10.24, "open": 10.23, "dayLow": 10.08, "dayHigh": 12.83, "regularMarketPreviousClose": 10.24, "regularMarketOpen": 10.23, "regularMarketDayLow": 10.08, "regularMarketDayHigh": 12.83, "forwardPE": -4.4059834, "volume": 2418016, "regularMarketVolume": 2418016, "averageVolume": 886150, "averageVolume10days": 1455360, "averageDailyVolume10Day": 1455360, "bid": 9.12, "ask": 13.26, "bidSize": 200, "askSize": 200, "marketCap": 597462464, "fiftyTwoWeekLow": 2.61, "fiftyTwoWeekHigh": 13.6, "fiftyDayAverage": 6.9304, "twoHundredDayAverage": 4.6564, "currency": "USD", "enterpriseValue": 907749056, "floatShares": 55373893, "sharesOutstanding": 57949800, "sharesShort": 8918540, "sharesShortPriorMonth": 11978822, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.1539, "heldPercentInsiders": 0.04445, "heldPercentInstitutions": 0.43677, "shortRatio": 6.15, "shortPercentOfFloat": 0.161, "impliedSharesOutstanding": 57949800, "bookValue": -2.66, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -185375008, "trailingEps": -3.14, "forwardEps": -2.34, "enterpriseToEbitda": -5.262, "52WeekChange": 1.8718662, "SandP52WeekChange": 0.2421279, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "OMER", "underlyingSymbol": "OMER", "shortName": "Omeros Corporation", "longName": "Omeros Corporation", "firstTradeDateEpochUtc": 1255008600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "3f7c487e-99e5-35b0-97bc-8da48930057f", "messageBoardId": "finmb_32388", "gmtOffSetMilliseconds": -18000000, "currentPrice": 10.31, "recommendationMean": 3.0, "recommendationKey": "hold", "totalCash": 123157000, "totalCashPerShare": 2.125, "ebitda": -172508992, "totalDebt": 433444000, "quickRatio": 2.329, "currentRatio": 2.965, "returnOnAssets": -0.26872998, "freeCashflow": -133369504, "operatingCashflow": -154648000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-21"}]